Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers.
Target Price
The average target price of KPTI is 16 and suggests 159% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell